Medically reviewed by Drugs.com. Last updated on Jun 2, 2019.
(nye troe PRUS ide)
- Nitroprusside Sodium
- Sodium Nitroferricyanide
- Sodium Nitroprusside
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Intravenous, as sodium:
Nipride RTU: 20 mg/100 mL in NaCl 0.9% (100 mL)
Nitropress: 25 mg/mL (2 mL)
Generic: 25 mg/mL (2 mL)
Solution, Intravenous, as sodium [preservative free]:
Nipride RTU: 10 mg/50 mL in NaCl 0.9% (50 mL [DSC]); 50 mg/100 mL in NaCl 0.9% (100 mL)
Generic: 25 mg/mL (2 mL)
Brand Names: U.S.
- Nipride RTU
Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance; will increase cardiac output by decreasing afterload; reduces aortal and left ventricular impedance
Nitroprusside combines with hemoglobin to produce cyanide and cyanmethemoglobin. Cyanide detoxification occurs via rhodanase-mediated conversion of cyanide to thiocyanate; rhodanase couples cyanide molecules to sulfane sulfur groups from a sulfur donor (eg, thiosulfate, cystine, cysteine). This process has limited capacity and may become overwhelmed with large exposures once sulfur donor supplies are exhausted resulting in toxicity.
Urine (as thiocyanate)
Onset of Action
Hypotensive effect: <2 minutes
Duration of Action
Hypotensive effect: 1-10 minutes
Nitroprusside, circulatory: ~2 minutes; Thiocyanate, elimination: ~3 days (may be doubled or tripled in renal failure)
Use: Labeled Indications
Acute decompensated heart failure (HF): Management of acute decompensated HF
Acute hypertension: Management of hypertensive crises; used for controlled hypotension to reduce bleeding during surgery
Off Label Uses
Hypertension during acute ischemic stroke
Based on the American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients with Acute Ischemic Stroke, nitroprusside given in the management of hypertension during acute ischemic stroke is listed as an alternative approach to patients with this condition.
Treatment of compensatory hypertension (aortic coarctation, arteriovenous shunting); to produce controlled hypotension during surgery in patients with known inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) requiring emergency surgery; acute heart failure associated with reduced systemic vascular resistance (eg, septic shock); congenital (Leber's) optic atrophy or tobacco amblyopia; concomitant use with sildenafil, tadalafil, vardenafil, or riociguat
Canadian labeling: Additional contraindication (not in US labeling): Hypersensitivity to nitroprusside or any component of the formulation; uncorrected anemia or hypovolemia; hepatic disease; severe renal disease; disease states associated with vitamin B12 deficiency
Acute hypertension: Initial: 0.3 to 0.5 mcg/kg/minute; may be titrated by 0.5 mcg/kg/minute every few minutes to achieve desired hemodynamic effect (Rhoney 2009); maximum dose: 10 mcg/kg/minute (for a maximum of 10 minutes). To avoid toxicity, some recommend a maximum dose of 2 mcg/kg/minute (Marik 2007).
Acute decompensated heart failure: IV: Initial: 5 to 10 mcg/minute; may be titrated rapidly (eg, up to every 5 minutes) to achieve desired hemodynamic effect; usual dosage range: 5 to 300 mcg/minute. Doses >400 mcg/minute are not recommended due to minimal added benefit and increased risk for thiocyanate toxicity (HFSA 2010).
Refer to adult dosing.
Hypertension, acute including hypertensive crisis: Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.3 to 0.5 mcg/kg/minute, titrate every 5 minutes to desired effect; usual dose: 3 to 4 mcg/kg/minute; maximum dose: 10 mcg/kg/minute (Chandar 2012; Hegenbarth 2008; NHBPEP 2004; Park 2014); increased infusion rates are correlated with increased cyanide concentrations (Hammer 2015); a study in pediatric postoperative cardiac surgery patients found patients with rates ≥1.8 mcg/kg/minute had increased cyanide concentrations (Moffett 2008); monitor cyanide levels with prolonged use (eg, >72 hours) (NHBPEP 2004)
Cardiac output maintenance/stabilization, postresuscitation (PALS [Kleinman 2010]): Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.5 to 1 mcg/kg/minute, titrate to desired effect; maximum dose: 8 mcg/kg/minute
Nitropress: Prior to administration, nitroprusside sodium should be further diluted by diluting 50 mg in 250 to 1,000 mL of D5W (preferred), LR, or NS.
Nipride RTU vial: Premixed solutions are available.
Use only clear solutions; solutions of nitroprusside exhibit a color described as brownish, brown, brownish-pink, light orange, and straw. Solutions are highly sensitive to light. Exposure to light causes decomposition, resulting in a highly colored solution of orange, dark brown or blue. A blue color indicates almost complete decomposition. Do not use discolored solutions (eg, blue, green, red) or solutions in which particulate matter is visible.
Prepared solutions should be wrapped as soon as possible with aluminum foil or other opaque material to protect from light.
IV: IV infusion only; infusion pump required. Due to potential for excessive hypotension, continuously monitor patient’s blood pressure during therapy. Product should always be protected from light, even during administration.
Nitropress, Nipride RTU vial: Store at 20°C to 25°C (68°F to 77°F). Protect from light; recommended to store in carton until used.
Stability of parenteral admixture in D5W, LR, or NS at room temperature (25°C) and at refrigeration temperature (4°C) is 24 hours.
Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. Consider therapy modification
Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Monitor therapy
Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Blood Pressure Lowering Agents: May enhance the hypotensive effect of Nitroprusside. Monitor therapy
Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Monitor therapy
Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Avoid combination
Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Monitor therapy
Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Monitor therapy
Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Monitor therapy
Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy
Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine. Monitor therapy
Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Consider therapy modification
Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Monitor therapy
Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Nitroprusside. Avoid combination
Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Monitor therapy
Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy
Riociguat: May enhance the hypotensive effect of Nitroprusside. Avoid combination
Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy
Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapy
Frequency not defined:
Cardiovascular: Bradycardia, ECG changes, flushing, palpitations, severe hypotension, substernal pain, tachycardia
Central nervous system: Apprehension, dizziness, headache, increased intracranial pressure, restlessness
Dermatologic: Diaphoresis, localized erythematous streaking, skin rash
Endocrine & metabolic: Hypothyroidism
Gastrointestinal: Abdominal pain, intestinal obstruction, nausea, retching
Hematologic & oncologic: Decreased platelet aggregation, methemoglobinemia
Local: Irritation at injection site
Neuromuscular & skeletal: Muscle twitching
ALERT: U.S. Boxed WarningAppropriate administration:
Nitropress: After reconstitution, nitroprusside is not suitable for direct injection. The reconstituted solution must be further diluted in dextrose 5% injection before infusion.Hypotension:
Nitroprusside can cause precipitous decreases in blood pressure. In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Use only when available equipment and personnel allow blood pressure to be continuously monitored.Cyanide toxicity:
Except when used briefly or at low (less than 2 mcg/kg/min) infusion rates, nitroprusside injection gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels. The usual dose rate is 0.5 to 10 mcg/kg/min, but infusion at the maximum dose rates should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, terminate administration immediately. Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.
Concerns related to adverse effects:
• Cyanide toxicity: [US Boxed Warning]: Except when used briefly or at low (<2 mcg/kg/minute) infusion rates, nitroprusside gives rise to large cyanide quantities. Do not use the maximum dose for more than 10 minutes; if blood pressure is not controlled by the maximum rate (ie, 10 mcg/kg/minute) after 10 minutes, discontinue infusion. Monitor for cyanide toxicity via acid-base balance and venous oxygen concentration; however, clinicians should note that these indicators may not always reliably indicate cyanide toxicity. Patients at risk of cyanide toxicity include those who are malnourished, have hepatic impairment, or those undergoing cardiopulmonary bypass, or therapeutic hypothermia (Rindone 1992). Discontinue use of nitroprusside if signs and/or symptoms of cyanide toxicity (eg, metabolic acidosis, decreased oxygen saturation, bradycardia, confusion, convulsions) occur. Although not routinely done, sodium thiosulfate has been co-administered with nitroprusside using a 10:1 ratio of sodium thiosulfate to nitroprusside when higher doses of nitroprusside are used (eg, 4 to 10 mcg/kg/minute) for extended periods of time in order to prevent cyanide toxicity (Shulz 2010; Varon 2008); thiocyanate toxicity may still occur with this approach (Rindone 1992). The use of other agents (eg, clevidipine, labetalol, nicardipine) should be considered if blood pressure is not controlled with nitroprusside.
• Hypotension: [US Boxed Warning]: Excessive hypotension resulting in compromised perfusion of vital organs may occur; continuous blood pressure monitoring by experienced personnel is required.
• Increased intracranial pressure: Use may elevate intracranial pressure; in patients whose intracranial pressure is already elevated, use only with extreme caution.
Methemoglobinemia: Nitroprusside can cause a dose-dependent conversion of hemoglobin to methemoglobin. Methemoglobinemia should be suspected in any patient receiving >10 mg/kg of nitroprusside and exhibiting signs of impaired oxygen delivery despite adequate cardiac output and arterial pO2. Symptomatic patients, regardless of methemoglobin level should be treated with methylene blue (first-line). Treatment is suggested if level is ≥30% even if asymptomatic unless patient has a preexisting condition (eg, coronary artery disease) and are incapable of tolerating reductions in oxygen carrying capacity then treatment is suggested if level reaches 10% (Cortazzo 2013).
• Thiocyanate toxicity: Can occur in patients with renal impairment or those on prolonged infusions (ie, >3 mcg/kg/minute for >72 hours).
• Anemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing anemia prior to use when possible.
• Hepatic impairment: Use with extreme caution in patients with hepatic impairment.
• Hypovolemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing hypovolemia prior to use when possible.
• Myocardial infarction: Use caution in patients with acute myocardial infarction because of hemodynamic effects and possible coronary steal.
• Renal impairment: Use with extreme caution in patients with renal impairment; use the lowest end of the dosage range; monitor thiocyanate concentrations closely.
• Appropriate administration: Nitropress: [US Boxed Warning]: Solution must be further diluted with 5% dextrose in water. Do not administer by direct injection.
Blood pressure via arterial line and heart rate (cardiac monitor and blood pressure monitor required) (Friedrich 1995); monitor for cyanide and thiocyanate toxicity; monitor venous oxygen saturation; monitor acid-base status as acidosis can be the earliest sign of cyanide toxicity; monitor thiocyanate levels if requiring prolonged infusion (>3 days) or dose >3 mcg/kg/minute or patient has renal dysfunction; monitor cyanide blood levels (if available with appropriate turnaround time) in patients with decreased hepatic function
Consult individual institutional policies and procedures.
Pregnancy Risk Factor
Animal studies have shown that nitroprusside may cross the placental barrier and result in fetal cyanide levels that are dose-related to maternal nitroprusside levels. However, information related to use in pregnancy is limited.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber signs of acidosis (confusion, fast breathing, tachycardia, abnormal heartbeat, severe abdominal pain, nausea, vomiting, fatigue, shortness of breath, or loss of strength and energy), signs of methemoglobinemia (blue or gray color of the lips, nails, or skin; abnormal heartbeat; seizures; severe dizziness or passing out; severe headache; fatigue; loss of strength and energy; or shortness of breath), severe headache, small pupils, severe dizziness, passing out, or tinnitus (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about nitroprusside
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: agents for hypertensive emergencies
- Sodium Nitroprusside (AHFS Monograph)
- Sodium Nitroprusside (FDA)
- Sodium Nitroprusside Injection (FDA)